Literature DB >> 34143766

The landscape of antibody binding in SARS-CoV-2 infection.

Anna S Heffron1, Sean J McIlwain2,3, Maya F Amjadi4, David A Baker1, Saniya Khullar2, Tammy Armbrust5, Peter J Halfmann5, Yoshihiro Kawaoka5, Ajay K Sethi6, Ann C Palmenberg7, Miriam A Shelef4,8, David H O'Connor1,9, Irene M Ong2,3,10.   

Abstract

The search for potential antibody-based diagnostics, vaccines, and therapeutics for pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has focused almost exclusively on the spike (S) and nucleocapsid (N) proteins. Coronavirus membrane (M), ORF3a, and ORF8 proteins are humoral immunogens in other coronaviruses (CoVs) but remain largely uninvestigated for SARS-CoV-2. Here, we use ultradense peptide microarray mapping to show that SARS-CoV-2 infection induces robust antibody responses to epitopes throughout the SARS-CoV-2 proteome, particularly in M, in which 1 epitope achieved excellent diagnostic accuracy. We map 79 B cell epitopes throughout the SARS-CoV-2 proteome and demonstrate that antibodies that develop in response to SARS-CoV-2 infection bind homologous peptide sequences in the 6 other known human CoVs. We also confirm reactivity against 4 of our top-ranking epitopes by enzyme-linked immunosorbent assay (ELISA). Illness severity correlated with increased reactivity to 9 SARS-CoV-2 epitopes in S, M, N, and ORF3a in our population. Our results demonstrate previously unknown, highly reactive B cell epitopes throughout the full proteome of SARS-CoV-2 and other CoV proteins.

Entities:  

Year:  2021        PMID: 34143766     DOI: 10.1371/journal.pbio.3001265

Source DB:  PubMed          Journal:  PLoS Biol        ISSN: 1544-9173            Impact factor:   8.029


  21 in total

Review 1.  Applications of Peptide Microarrays in Autoantibody, Infection, and Cancer Detection.

Authors:  Carsten Grötzinger
Journal:  Methods Mol Biol       Date:  2023

2.  Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19.

Authors:  David J Gregory; Augustin Vannier; Akiro H Duey; Tyler J Roady; Richard K Dzeng; Maia N Pavlovic; Michael H Chapin; Sonia Mukherjee; Hannah Wilmot; Nic Chronos; Richelle C Charles; Edward T Ryan; Regina C LaRocque; Tyler E Miller; Wilfredo F Garcia-Beltran; Julia C Thierauf; A John Iafrate; Steven Mullenbrock; Mark D Stump; Randall K Wetzel; Roberto D Polakiewicz; Vivek Naranbhai; Mark C Poznansky
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

3.  Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2.

Authors:  Heidi Auerswald; Chanreaksmey Eng; Sokchea Lay; Saraden In; Sokchea Eng; Hoa Thi My Vo; Charya Sith; Sokleaph Cheng; Gauthier Delvallez; Vann Mich; Ngy Meng; Ly Sovann; Kraing Sidonn; Jessica Vanhomwegen; Tineke Cantaert; Philippe Dussart; Veasna Duong; Erik A Karlsson
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 4.  Advances and Utility of the Human Plasma Proteome.

Authors:  Eric W Deutsch; Gilbert S Omenn; Zhi Sun; Michal Maes; Maria Pernemalm; Krishnan K Palaniappan; Natasha Letunica; Yves Vandenbrouck; Virginie Brun; Sheng-Ce Tao; Xiaobo Yu; Philipp E Geyer; Vera Ignjatovic; Robert L Moritz; Jochen M Schwenk
Journal:  J Proteome Res       Date:  2021-10-21       Impact factor: 5.370

5.  Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors.

Authors:  Wihan Adi; Dhruv Biswas; Miriam A Shelef; Filiz Yesilkoy
Journal:  Biomed Opt Express       Date:  2022-03-16       Impact factor: 3.562

6.  High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.

Authors:  Sai Priya Anand; Jérémie Prévost; Jonathan Richard; Josée Perreault; Tony Tremblay; Mathieu Drouin; Marie-Josée Fournier; Antoine Lewin; Renée Bazin; Andrés Finzi
Journal:  Transfusion       Date:  2021-02-18       Impact factor: 3.337

7.  Apropos of Universal Epitope Discovery for COVID-19 Vaccines: A Framework for Targeted Phage Display-Based Delivery and Integration of New Evaluation Tools.

Authors:  Christopher Markosian; Daniela I Staquicini; Prashant Dogra; Esteban Dodero-Rojas; Fenny H F Tang; Tracey L Smith; Vinícius G Contessoto; Steven K Libutti; Zhihui Wang; Vittorio Cristini; Paul C Whitford; Stephen K Burley; José N Onuchic; Renata Pasqualini; Wadih Arap
Journal:  bioRxiv       Date:  2021-08-30

8.  Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients.

Authors:  María Martin-Vicente; Raquel Almansa; Isidoro Martínez; Ana P Tedim; Elena Bustamante; Luis Tamayo; César Aldecoa; José Manuel Gómez; Gloria Renedo; Jose Ángel Berezo; Jamil Antonio Cedeño; Nuria Mamolar; Pablo García Olivares; Rubén Herrán-Monge; Ramón Cicuendez; Pedro Enríquez; Alicia Ortega; Noelia Jorge; Cristina Doncel; Amanda de la Fuente; Juan Bustamante-Munguira; María José Muñoz-Gómez; Milagros González-Rivera; Carolina Puertas; Vicente Más; Mónica Vázquez; Felipe Pérez-García; Jesús Rico-Feijoo; Silvia Martín; Anna Motos; Laia Fernandez-Barat; Jose María Eiros; Marta Dominguez-Gil; Ricard Ferrer; Ferrán Barbé; Wysali Trapiello; David J Kelvin; Jesús F Bermejo-Martin; Salvador Resino; Antoni Torres
Journal:  J Intern Med       Date:  2021-10-05       Impact factor: 13.068

Review 9.  Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.

Authors:  Qilong Tang; Raymond J Owens; James H Naismith
Journal:  Viruses       Date:  2021-11-03       Impact factor: 5.048

10.  ELISA-Based Analysis Reveals an Anti-SARS-CoV-2 Protein Immune Response Profile Associated with Disease Severity.

Authors:  Charline Herrscher; Sébastien Eymieux; Christophe Gaborit; Hélène Blasco; Julien Marlet; Karl Stefic; Philippe Roingeard; Leslie Grammatico-Guillon; Christophe Hourioux
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.